We further postulated that a group of non-responding HNSCC models represents patients who either (a) would not benefit from a PI3K therapy, or (b) would benefit from a multi-targeting approach that simultaneously impairs PI3K bypass signaling. Here, PIK3CA is linked to head and neck squamous cell carcinoma.